I
n Mexico, the prevalence of hypertension (arterial blood pressure [BP] ≥140/90 mm Hg) in adults 20 years and older was estimated as 31.5%, according to the National Health and Nutrition Survey (ENSANUT 2012). 1 intestinal resection, diuretic initiation during the previous 5 days to enrollment, active infection, pregnancy, and breastfeeding.
A detailed medical history and physical examination were applied to all participants. Laboratory workup included a 24-hour urine collection and a fasting blood sample. Previous known diagnosis of hypertension and diabetes mellitus was recorded, as well as medication they had received. Body weight and height were measured; overweight was defined as a body mass index (BMI) between 25.0 and 29.9 kg/m 2 and obesity as a BMI ≥30.0 kg/m 2 . The average of 3 BP determinations was recorded. BP was measured after 5-minute rest, and then a measurement was recorded every one minute, in a sitting position, on the right arm, employing an Omron HEM-907XL sphygmomanometer (Omron Health Care Inc, IL).
CVD risk was assessed by three 10-year CVD risk calculators: the Atherosclerotic CVD (ASCVD) calculator, 9 ,10 the Framingham calculator using lipids, and the Framingham calculator using BMI. 11 For each subject, the requirements for nonpharmacological and pharmacological treatment were determined according to both ACC/ AHA 2017 and JNC 7 guidelines. 2, 4 In addition, need for pharmacological treatment was simulated with each Framingham score using an estimated CVD risk ≥15%.
Data from SALMEX cohort were extrapolated to Mexico City population based on the 2010 National Population Survey (National Institute of Geography and Informatics 2010), considering the age distribution for Mexico City residents 20 to 64 years old. 6 Annual cost estimates for the initial evaluation and follow-up visits for the new extrapolated hypertensive subjects in Mexico City were calculated based on the 2018 list of break-even costs of a public institution in Mexico City (National Medical Science and Nutrition Institute Salvador Zubirán), 12 adjusted to 2018 US dollars (as per exchange rate on January 24, 2018).
According to ACC/AHA 2017 guidelines, the estimation includes an individual annual cost of $79 for those who require pharmacological treatment (an initial medical evaluation and 4 follow-up evaluations, not considering pharmacological treatment cost per se) and $53 for those who only require nonpharmacological intervention (an initial medical evaluation and 1 subsequent evaluation).
Ethics
The Health Research and Ethics Committees of the National Medical Science and Nutrition Institute Salvador Zubirán (Reference no. 191) approved the study. The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
Statistics
Hypertension prevalence was described by sex and age groups and was adjusted to 2010 age-sex distribution of the Mexico City adult population. Modifications to the requirements of pharmacological and nonpharmacological treatment and the annual cost of follow-up were described in the SALMEX cohort according to the 2 hypertension definitions (JNC 7 and ACC/AHA 2017) and extrapolated to Mexico City population. κ indexes were calculated to determine the correlation of using the Framingham score (with lipids or with BMI) compared with using the ASCVD score, to define which patients should receive pharmacological treatment.
Results
A total of 990 participants from the SALMEX cohort were included in this study. The median age was 38 years (interquartile range, 31-46) and 61.8% were female. Table 1 shows the characteristics of the complete study population.
Among the study population, women were older than men ( The prevalence of hypertension among SALMEX population increased from 16.2% (JNC 7) to 37.4% (ACC/AHA 2017). When the results were extrapolated to the Mexico City age-matched population according to the National Institute of Geography and Informatics 2010 census, prevalence of hypertension increased from 18.0% to 39.3%. As expected, prevalence of hypertension was higher in men in both scenarios. These increments in prevalence were preserved in all age groups (Table 2) .
According to ACC/AHA 2017 guidelines, 37.4% (n=370) of SALMEX participants would require nonpharmacological intervention, a proportional increment of 111.4% when compared with 17.7% (n=175) considering the JNC 7 guideline. The indication to begin pharmacological treatment in the SALMEX cohort had a modest increase from 11.2% (JNC 7) to 12.5% (ACC/AHA 2017). When Mexico City age-matched population was analyzed, an increment of 92.3% in nonpharmacological intervention, and 6.6% in pharmacological treatment, was projected (Table 3) .
Estimated annual cost of an initial evaluation and 1-year follow-up for the new subjects with hypertension in Mexico City, according to guideline recommendations, corresponds to $59 278 928 (Table 4) (Table 5) .
Discussion
On the basis of the SALMEX cohort and adjusted to the 2010 age-sex distribution of Mexico City population, hypertension prevalence increased >2-fold (18.0%-39.3%) compared with the previous recommendations. However, there was a small increase in the need for pharmacological treatment (2.4%, from 19.4% to 21.8%). These results are similar to those previously published for the Hispanic population based on NHANES (National Health and Nutrition Examination Survey) 2011-2014. 2, 5 Therefore, the main impact of new definition is on nonpharmacological treatment.
These new hypertensive Mexican adults should adopt the recommendations ACC/AHA 2017 for nonpharmacological treatment, which have been proven to be difficult in the Mexican population. These recommendations include weight loss and physical activity, a heart-healthy diet with sodium intake reduction (<1500 mg/d of sodium or 5 g/d of salt), potassium supplementation when appropriate, and alcohol avoidance, all of them to reduce BP in adults with hypertension.
In Mexico, the ENSANUT 2012 1 (which included 46 303 subjects older than 20 years) reported a combined prevalence of hypertension and obesity of 42.3%, and up to 16% of them were not compliant with the physical activity recommendations. In addition, mean dietary sodium intake in Mexico has been evaluated as high. 7, 8, 13 In a sample of the SALMEX cohort, the mean daily sodium intake estimated by 24-hour urinary sodium excretion was 3497.2 mg/d. Furthermore, around 89.5% of the SALMEX cohort participants had a salt intake higher than 5 g/d, with 44% consuming >9 g/d of salt. 7 Extrapolation of SALMEX cohort results to Mexico City population estimated an annual cost of $59 278 928 to provide an appropriate for follow-up, a proportional increment of 73%. This represents approximately two-thirds of the Mexican healthcare system's budget for universal vaccination program of all Mexico ($94 715 983). 14 Given that the new ACC/AHA 2017 guidelines recommend estimating CVD risk to guide the need for pharmacological treatment, we calculated CVD risk using the Framingham lipids and BMI scores and compared them with the ASCVD score, and we found an excellent correlation between these scores (κ indexes of 0.981 and 0.972, respectively). On the basis of these results, physicians could use the Framingham BMI score to assess the need to start treatment during the initial evaluation, without the cost and waiting time of a sample test for lipids. Correlation between Framingham lipids and BMI scores has been studied before 15 and found to be similar to ours. The only caveat with their use is to always use the same tool to calculate the score throughout the follow-up of any given subject.
The strength of our study is that all BP measurements were in accordance to the recommendations for accurate measurement and documentation of BP, 16 and blood samples were used to calculate CVD risk. Proper BP measurement is of utmost importance and has significant implications in the outcomes and benefits of adequate control. Therefore, SPRINT trial had a specific methodology that could have implications on the results observed, as there are important variations in BP measurements between research and clinical practice. 17 The methodology used in SALMEX cohort for BP measurement was similar to that used in the SPRINT, †Hypercholesterolemia was defined as a blood cholesterol concentration ≥200 mg/dL. ‡Blood HDL cholesterol concentration <40 mg/dL. §Blood LDL cholesterol concentration ≥130 mg/dL. ‖Hypertriglyceridemia was defined as blood triglyceride concentration ≥150 mg/dL. ¶Chronic kidney disease was defined as an estimated glomerular filtration rate <60 mL min −1 1.73 m −2 of body surface area or a urinary albumin/creatinine ratio ≥200 mg/g. #Information available for 984 subjects.
except for the presence of an observer during the procedure. This allowed us to reliably establish the prevalence of hypertension and estimate the increase in pharmacological and nonpharmacological treatment. The financial impact of the projected increment in follow-up costs of hypertensive individuals because of the new hypertension definition has not been fully evaluated in a pharmacoeconomic model that would consider prevention of complications and hospitalizations. This needs to be fully evaluated in future analyses.
In addition, it is important to consider that the SALMEX cohort is not a representative sample of Mexico City population, or of Mexico as a country. Prevalence of hypertension in Mexico varies according to geographic area, urbanization, and socioeconomic level. This was observed in ENSANUT 2012, where prevalence was significantly higher (P<0.05) in the northern region of the country (36.4%) when compared with the south (28.5%) and in urban localities (31.9%) when compared with rural areas (29.9%). 18, 19 Likewise, there are differences in the percentage of adults with controlled hypertension. These differences could attribute to differences in prevalence of obesity, smoking, physical activity, and sodium consumption, factors associated to hypertension and that complicate its control. Therefore, extrapolations of the results of our study must consider potential population differences.
At present, the systematic implementation of the new ACC/AHA 2017 guidelines is not feasible in our population. Our health system lacks the required infrastructure and financial capability to provide adequate follow-up to this significantly larger population of new hypertensive Mexican adults, which in most cases will only require nonpharmacological interventions. This would imply a significant expansion of healthcare facilities and personnel as well as redirecting a limited budget. Furthermore, the limitation of our infrastructure would not allow to assess patient compliance and effectiveness of the nonpharmacological interventions proposed by the new ACC/AHA 2017 guidelines. In our population, there are no cohort studies where the benefit of intensive BP control has been evaluated. However, we are aware of the evidence on which the new guidelines are based. In SPRINT, an intensive BP control reduced the rate of cardiovascular events, and this difference was at the expense of the non-black group of patients, where the Hispanic population constituted 15.3% (n=984 Hispanics) of 6414 non-blacks. Therefore, we consider that the evaluation of cardiovascular risk should be an important element in the decision to initiate pharmacological treatment in the subgroup of patients with BP figures in the range systolic BP 130-139/diastolic BP 80-89 mm Hg.
We consider that at present, the JNC 7 classification and recommendations should be maintained, adding the criteria 
Perspectives
The adoption of the new 2017 ACC/AHA guideline for high BP in adults in Mexican population has implications not only on its prevalence but also on medical follow-up costs. In addition, the Framingham BMI score represents an attractive cost-effective alternative to assess cardiovascular risk at diagnosis. A large, randomized selection of Mexican population that includes a complete evaluation with blood samples to assess individual cardiovascular risk would be required to test the previously described findings in a larger population. *Excluding cost of pharmacological treatment in those indicated. Extrapolation based on the 2010 age distribution of Mexico City population. †Individual cost per year included basic testing at diagnosis and the appropriate medical evaluations according to ACC/AHA 2017 hypertension guidelines, considering initial medical evaluations and 1 follow-up per year for the hypertensive subjects that only require nonpharmacological intervention, and initial medical evaluation and 4 follow-up evaluations for those who need pharmacological treatment. Initial medical evaluation includes basic laboratory tests for primary hypertension. Cost based on a list of service costs of a public hospital in Mexico City, adjusted to 2018 US dollars. †Exclusion of subjects already treated.
